M2 Presswire - SMITHKLINE BEECHAM: Smithkline Beecham & SkyePharma si sign agreement to develop once daily Requip.
M2 PRESSWIRE-17 September 1999-SMITHKLINE BEECHAM: Smithkline Beecham and SkyePharma sign agreement to develop once daily Requip (C)1994-99 M2 COMMUNICATIONS LTD RDATE:150999 LONDON — SmithKline Beecham (SB) and SkyePharma PLC announced today that they have entered into a development and licensing agreement for a once-daily version of SB’s anti-Parkinsonion drug, Requip (ropinirole), using SkyePharma’s GEOMATRIX oral delivery technology.
Related Results
Requip for RLSRequip reduces risk of dyskinesiasRequip now has generic competitorsGSK’s Requip significantly improves restless legs syndromeRequip shows use for restless legs syndrome.
The new formulation is expected to provide a simplified regime for patients on Requip therapy thus improving patient convenience. Under …
Read the rest of this article with a Free Trial at HighBeam Research.
